BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/21/2024 9:11:33 AM | Browse: 162 | Download: 430
 |
Received |
|
2023-11-19 12:22 |
 |
Peer-Review Started |
|
2023-11-19 12:24 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2023-12-15 02:07 |
 |
Revised |
|
2023-12-18 18:37 |
 |
Second Decision |
|
2024-01-23 02:53 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2024-01-23 06:21 |
 |
Articles in Press |
|
2024-01-23 06:21 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2024-02-02 00:49 |
 |
Publish the Manuscript Online |
|
2024-02-21 09:11 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Meta-Analysis |
Article Title |
Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis
|
Manuscript Source |
Invited Manuscript |
All Author List |
Maja Cigrovski Berkovic, Alessandro Coppola, Vibor Sesa, Anna Mrzljak and Quirino Lai |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Maja Cigrovski Berkovic, MD, PhD, Assistant Professor, Department for Sport and Exercise Medicine, Faculty of Kinesiology University of Zagreb, Horvacanski zavoj 15, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com |
Key Words |
Pancreatic neuroendocrine tumors; Type 2 diabetes mellitus; Prognosis; Treatment; Metformin |
Core Tip |
Pancreatic neuroendocrine tumors (pNETs) are a challenge to diagnose and treat. Often curative treatments are not possible and additional therapy aimed at symptom relief and tumor cell growth inhibition is warranted. Unfortunately, a significant number of pNET patients do not respond to the above-mentioned medical treatments or show resistance. Therefore, exploring the risk factors and additional therapeutics is of importance. This systematic review and meta-analysis showed that in patients with type 2 diabetes mellitus (T2DM), the risk for pNET insurgence was significantly increased. In addition, T2DM was a significant predictor of poor tumor free survival. Results on the role of metformin in the setting of diagnosis and prognosis of pNET due to paucity of data and data heterogeneity failed to show statistical relevance of its use, although there are indices that it might positively impact the progression free survival. |
Publish Date |
2024-02-21 09:11 |
Citation |
Cigrovski Berkovic M, Coppola A, Sesa V, Mrzljak A, Lai Q. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis. World J Gastroenterol 2024; 30(7): 759-769 |
URL |
https://www.wjgnet.com/1007-9327/full/v30/i7/759.htm |
DOI |
https://dx.doi.org/10.3748/wjg.v30.i7.759 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345